Dave Singh

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 39

Top Topics

Ankylosing Spondylitis

Chronic Obstructive Pulmonary Disease

Top Venues

British journal of clinical pharmacology

American journal of respiratory and critical care medicine

Respirology (Carlton, Vic.)

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Dave Singh, Meilan K Han, Nathaniel Mark Hawkins, John R Hurst, Janwillem W H Kocks, Neil Skolnik, Daiana Stolz, Jad El Khoury, Chris P Gale
Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Advances in therapy 41 (6) (2024)
Dave Singh, Meilan K Han, Nathaniel Mark Hawkins, John R Hurst, Janwillem W H Kocks, Neil Skolnik, Daiana Stolz, Jad El Khoury, Chris P Gale
Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Advances in therapy 41 (6) (2024)
Christian Friedrich, Dave Singh, Klaus Francke, Stefan Klein, Terence Hetzel, Oliver Zolk, Isabella Gashaw, Christian Scheerans, Alyn Morice
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men. British journal of clinical pharmacology 90 (8) (2024)
Christian Friedrich, Dave Singh, Klaus Francke, Stefan Klein, Terence Hetzel, Oliver Zolk, Isabella Gashaw, Christian Scheerans, Alyn Morice
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men. British journal of clinical pharmacology (2024)
Dave Singh, Meilan K Han, Nathaniel Mark Hawkins, John R Hurst, Janwillem W H Kocks, Neil Skolnik, Daiana Stolz, Jad El Khoury, Chris P Gale
Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Advances in therapy (2024)
Dave Singh, Meilan K Han, Nathaniel Mark Hawkins, John R Hurst, Janwillem W H Kocks, Neil Skolnik, Daiana Stolz, Jad El Khoury, Chris P Gale
Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Advances in therapy 41 (6) (2024)
Alvar Agustí, Bartolome R Celli, Gerard J Criner, David M G Halpin, Antonio Anzueto, Peter Barnes, Jean Bourbeau, MeiLan K Han, Fernando J Martinez, Maria Montes de Oca, Kevin Mortimer, Alberto Papi, Ian Douglas Pavord, Nicholas Roche, Sundeep Salvi, Don D Sin, Dave Singh, Robert Stockley, M Victorina López Varela, Jadwiga A Wedzicha, Claus F Vogelmeier
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Respirology (Carlton, Vic.) (2023)
Alvar Agustí, Bartolome R Celli, Gerard J Criner, David M G Halpin, Antonio Anzueto, Peter Barnes, Jean Bourbeau, MeiLan K Han, Fernando J Martinez, Maria Montes de Oca, Kevin Mortimer, Alberto Papi, Ian Douglas Pavord, Nicholas Roche, Sundeep Salvi, Don D Sin, Dave Singh, Robert Stockley, M Victorina López Varela, Jadwiga A Wedzicha, Claus F Vogelmeier
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Respirology (Carlton, Vic.) (2023)
Thomas M A Wilkinson, Anthony De Soyza, Miles W Carroll, James D Chalmers, Michael G Crooks, Gareth Griffiths, Manu Shankar-Hari, Ling-Pei Ho, Alex Robert Horsley, Chris Kell, Beatriz Lara Gallego, Biswa Mishra, Rachel Moate, Clive Page, Hitesh Pandya, Jason Raw, Fred Reid, Dinesh Saralaya, Ian C Scott, Salman Siddiqui, Andy Ustianowski, Natalie van Zuydam, Ashley Woodcock, Dave Singh
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2. ERJ open research 9 (5) (2023)
Christian Domingo Ribas, Dave Singh
The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription. Advances in therapy (2023)
Mona Bafadhel, Klaus Friedrich Rabe, Fernando J Martinez, Dave Singh, Patrick Darken, Martin Jenkins, Magnus Aurivillius, Mehul S Patel, Paul Dorinsky
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. International journal of chronic obstructive pulmonary disease 17 (2022)
Dave Singh, Gabriel Garcia, Kittipong Maneechotesuwan, Peter T Daley-Yates, Elvis Malcolm Irusen, Bhumika Aggarwal, Isabelle Boucot, Norbert Berend
New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management. Advances in therapy 39 (5) (2022)
Thomas Southworth, Zala Jevnikar, Christopher McCrae, Dave Singh
A sputum 6-gene signature predicts airway inflammation endotypes and exacerbation frequency in chronic obstructive pulmonary disease. Biomarkers in medicine 16 (4) (2022)
Mona Bafadhel, Klaus Friedrich Rabe, Fernando J Martinez, Dave Singh, Patrick Darken, Martin Jenkins, Magnus Aurivillius, Mehul S Patel, Paul Dorinsky
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. International journal of chronic obstructive pulmonary disease 17 (2022)
Mona Bafadhel, Klaus Friedrich Rabe, Fernando J Martinez, Dave Singh, Patrick Darken, Martin Jenkins, Magnus Aurivillius, Mehul S Patel, Paul Dorinsky
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. International journal of chronic obstructive pulmonary disease 17 (2022)
Dave Singh, Christopher E Brightling
Bronchiectasis, the Latest Eosinophilic Airway Disease: What About the Microbiome? American journal of respiratory and critical care medicine 205 (8) (2022)
Dave Singh, John R Hurst, Fernando J Martinez, Klaus Friedrich Rabe, Mona Bafadhel, Martin Jenkins, Domingo Salazar, Paul Dorinsky, Patrick Darken
Predictive modeling of COPD exacerbation rates using baseline risk factors. Therapeutic advances in respiratory disease 16 (2022)
Dave Singh, Alvar Agusti, Fernando J Martinez, Alberto Papi, Ian D Pavord, Jadwiga A Wedzicha, Claus F Vogelmeier, David M G Halpin
Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. American journal of respiratory and critical care medicine 206 (1) (2022)
Philip J Thompson, Gerard J Criner, Mark T Dransfield, David M G Halpin, MeiLan K Han, David A Lipson, Ghassan J Maghzal, Fernando J Martinez, Dawn Midwinter, Dave Singh, Lee Tombs, Robert A Wise
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial. Respirology (Carlton, Vic.) 27 (12) (2022)
Dave Singh, Rainard Fuhr, Nicholas P Bird, Sarah Mole, Kelly Hardes, Yau Lun Man, Anthony Cahn, Steven W Yancey, Isabelle J Pouliquen
A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. British journal of clinical pharmacology (2021)
Dave Singh, Gerard J Criner, Ian Naya, Paul W Jones, Lee Tombs, David A Lipson, MeiLan K Han
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer? Respiratory research 22 (1) (2021)
Dave Singh, Simon Lea, Alexander G Mathioudakis
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs 81 (16) (2021)
Dave Singh
Pharmacological treatment of stable chronic obstructive pulmonary disease. Respirology (Carlton, Vic.) 26 (7) (2021)
Dave Singh, Rainard Fuhr, Lali Jimenez, Ulrika Wählby-Hamrén, Alexandra Jauhiainen, Marie-Pierre Malice, Victor Balaguer, Alejhandra Lei, Ajay Aggarwal, Carol Astbury, Ioannis Psallidas
A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine 199 (10) (2020)
Dave Singh, Aida Emirova, Catherine Francisco, Debora Santoro, Mirco Govoni, Marie Anna Nandeuil
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. Respiratory research 21 (1) (2020)
Dave Singh, Johann Christian Virchow, Giorgio Walter Canonica, Andrea Vele, Maxim Kots, George Georges, Alberto Papi
Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respiratory research 21 (1) (2020)
Natalie Jackson, Jethin Rafique, Dave Singh
Identifying small airway dysfunction in asthma in clinical practice. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia 46 (2) (2020)
Peter T Daley-Yates, Noushin Brealey, Sebin Thomas, Daren Austin, Shaila Shabbir, Tim Harrison, Dave Singh, Neil Barnes
Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. British journal of clinical pharmacology 87 (2) (2020)
Dave Singh, Gerard J Criner, Ian Naya, Paul W Jones, Lee Tombs, David A Lipson, MeiLan K Han
Measuring disease activity in COPD: is clinically important deterioration the answer? Respiratory research 21 (1) (2020)
David L Hava, Lisa Tan, Patrick Johnson, Aidan K Curran, Jason Perry, Steve Kramer, Katie Kane, Pauline Bedwell, Gary Layton, Clarie Swann, Dennis Henderson, Naimat Khan, Lucy Connor, Litza McKenzie, Dave Singh, James Roach
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. British journal of clinical pharmacology 86 (4) (2020)
Dave Singh, Jadwiga A Wedzicha, Salman Siddiqui, Alberto de la Hoz, Wenqiong Xue, Helgo Magnussen, Marc Miravitlles, James D Chalmers, Peter M A Calverley
Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respiratory research 21 (1) (2020)
Dave Singh, Frans van den Berg, Brian Leaker, Massimo Corradi, Sunny Jabbal, Sara Collarini, Valentina Mongelli, Luigi Santoro, Annalisa Piccinno, Sonia Biondaro, Brian Lipworth
Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler. British journal of clinical pharmacology 85 (4) (2019)
Dave Singh
One bronchodilator or two? Translating clinical trials into clinical practice. Respirology (Carlton, Vic.) 25 (4) (2019)
Dave Singh
Double combination inhalers in COPD: How to get your head around this data. Respirology (Carlton, Vic.) 23 (12) (2018)
Dave Singh, Arjun Ravi, Katie Kane, Tess Schmalbach, David L Hava
The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease. British journal of clinical pharmacology 84 (9) (2018)
Dave Singh
Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum. American journal of respiratory and critical care medicine 196 (9) (2017)
Dave Singh, Nicolas Roche, David Halpin, Alvar Agusti, Jadwiga A Wedzicha, Fernando J Martinez
Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine 194 (5) (2017)
Dave Singh, Jørgen Vestbo
Triple Therapy in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine 196 (8) (2017)
Dave Singh, Louise E Donnelly
Now We Know Who You Are: A Clear Description of Mononuclear Phagocyte Subsets in the Human Lung. American journal of respiratory and critical care medicine 193 (6) (2016)